Title of article
Montelukast and Coronavirus Disease 2019: A Scoping Review
Author/Authors
Sharifinejad ، Niusha Student Research Committee, Alborz Office of Universal Scientific Education and Research Network (USERN) - Alborz University of Medical Sciences , Sharafian ، Samin Department of Allergy and Clinical Immunology - Mofid Children’s Hospital - Shahid Beheshti University of Medical Sciences , Salekmoghadam ، Sana Student Research Committee - Alborz University of Medical Sciences , Tavakol ، Marzieh Non-communicable Diseases Research Center - Alborz University of Medical Sciences , Qorbani ، Mostafa Social Determinants of Health Research Center - Alborz University of Medical Sciences
From page
384
To page
393
Abstract
Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.
Keywords
COVID , 19 , Leukotriene antagonists , Leukotriene D4 receptor , Montelukast , SARS , CoV , 2
Journal title
Iranian Journal of Allergy, Asthma and Immunology
Journal title
Iranian Journal of Allergy, Asthma and Immunology
Record number
2668725
Link To Document